TY - JOUR
T1 - Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC
AU - Tanaka, Kentaro
AU - Sugisaka, Jun
AU - Shiraishi, Yoshimasa
AU - Watanabe, Yasutaka
AU - Daga, Haruko
AU - Azuma, Koichi
AU - Nishino, Kazumi
AU - Mori, Masahide
AU - Ota, Takayo
AU - Saito, Haruhiro
AU - Hata, Akito
AU - Sakaguchi, Tadashi
AU - Kozuki, Toshiyuki
AU - Akamatsu, Hiroaki
AU - Matsumoto, Hirotaka
AU - Tachihara, Motoko
AU - Wakuda, Kazushige
AU - Sato, Yuki
AU - Ozaki, Tomohiro
AU - Tsuchiya-Kawano, Yuko
AU - Yamamoto, Nobuyuki
AU - Nakagawa, Kazuhiko
AU - Okamoto, Isamu
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025/12
Y1 - 2025/12
N2 - Anti-vascular endothelial growth factor (VEGF) agents in combination with immunotherapies have improved outcomes for cancer patients, but predictive biomarkers have not been elucidated. We report here a preplanned analysis in the previously reported APPLE study, a phase 3 trial evaluating the efficacy of the bevacizumab in combination with atezolizumab, plus platinum chemotherapy in metastatic, nonsquamous non-small cell lung cancer (NSCLC). We investigated the correlation of serum VEGF-A and its isoforms at baseline with treatment response by using an enzyme-linked immunosorbent assay. We reveal that the addition of bevacizumab significantly improves the progression-free survival in patients with the low VEGF-A level. Our results demonstrate that measuring serum VEGF-A or its isoforms may identify NSCLC patients who are likely to benefit from the addition of bevacizumab to immunotherapy. These assays are easy to measure and have significant potential for further clinical development.
AB - Anti-vascular endothelial growth factor (VEGF) agents in combination with immunotherapies have improved outcomes for cancer patients, but predictive biomarkers have not been elucidated. We report here a preplanned analysis in the previously reported APPLE study, a phase 3 trial evaluating the efficacy of the bevacizumab in combination with atezolizumab, plus platinum chemotherapy in metastatic, nonsquamous non-small cell lung cancer (NSCLC). We investigated the correlation of serum VEGF-A and its isoforms at baseline with treatment response by using an enzyme-linked immunosorbent assay. We reveal that the addition of bevacizumab significantly improves the progression-free survival in patients with the low VEGF-A level. Our results demonstrate that measuring serum VEGF-A or its isoforms may identify NSCLC patients who are likely to benefit from the addition of bevacizumab to immunotherapy. These assays are easy to measure and have significant potential for further clinical development.
UR - http://www.scopus.com/inward/record.url?scp=105000683564&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=105000683564&partnerID=8YFLogxK
U2 - 10.1038/s41467-025-58186-7
DO - 10.1038/s41467-025-58186-7
M3 - Article
C2 - 40121197
AN - SCOPUS:105000683564
SN - 2041-1723
VL - 16
JO - Nature communications
JF - Nature communications
IS - 1
M1 - 2825
ER -
